All In Biotech

Drug Trial Radar · NCT06867094

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate-to-severe Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

170

Actual

Start

Mar 28, 2025

Primary completion

Aug 6, 2026

Study completion Oct 12, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study). * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.

Conditions

  • Colitis Ulcerative

Interventions

  • SAR441566Drug

    Pharmaceutical form: Tablet Route of administration: Oral

  • SAR441566 matching PlaceboDrug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving clinical remission at Week 12 by modified Mayo Score (mMS)Time frame: Week 12

Locations

117 sites in 24 countries. Site status is shown where the registry gives one.

  • GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400003

    Sun City, Arizona

  • Bristol Hospital- Site Number : 8400017

    Bristol, Connecticut

  • Novum Research- Site Number : 8400018

    Clermont, Florida

  • Clinical Research of Osceola- Site Number : 8400012

    Kissimmee, Florida

  • Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400002

    Miami Lakes, Florida

  • GCP Clinical Research- Site Number : 8400016

    Tampa, Florida

  • GI Alliance - Glenview- Site Number : 8400005

    Glenview, Illinois

  • Illinois Gastroenterology Group- Site Number : 8400004

    Gurnee, Illinois

  • University of Michigan Health System - Ann Arbor- Site Number : 8400010

    Ann Arbor, Michigan

  • Icahn School of Medicine at Mount Sinai- Site Number : 8400001

    New York, New York

  • Queens Village Primary Medical Center- Site Number : 8400011

    Queens Village, New York

  • NexGen Research- Site Number : 8400020

    Lima, Ohio

  • Frontier Clinical Research - Uniontown- Site Number : 8400006

    Uniontown, Pennsylvania

  • Medical University Of South Carolina - MUSC Health Ashley River Tower - ART- Site Number : 8400008

    Charleston, South Carolina

  • Gastro Health & Nutrition- Site Number : 8400007

    Katy, Texas

  • SI Research Associates- Site Number : 8400019

    Lubbock, Texas

  • Texas Digestive Disease Consultants - Southlake- Site Number : 8400015

    Southlake, Texas

  • University of Washington Medical Center- Site Number : 8400014

    Seattle, Washington

  • Washington Gastroenterology - Tacoma- Site Number : 8400009

    Tacoma, Washington

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320005

    Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Investigational Site Number : 0360003

    Kurralta Park, South Australia, Australia

  • Investigational Site Number : 0360005

    Richmond, Victoria, Australia

  • Investigational Site Number : 0400002

    Salzburg, Austria

  • Investigational Site Number : 0400001

    Vienna, Austria

  • Investigational Site Number : 0560002

    Ghent, Belgium

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • Hospital de Clinicas de Porto Alegre- Site Number : 0760002

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Ernesto Dornelles- Site Number : 0760003

    Porto Alegre, Rio Grande do Sul, Brazil

  • Investigational Site Number : 1000001

    Burgas, Bulgaria

  • Investigational Site Number : 1000003

    Rousse, Bulgaria

  • Investigational Site Number : 1000002

    Sofia, Bulgaria

  • Investigational Site Number : 1240004

    Kentville, Nova Scotia, Canada

  • Investigational Site Number : 1240006

    Ajax, Ontario, Canada

  • Investigational Site Number : 1240005

    Richmond Hill, Ontario, Canada

  • Investigational Site Number : 1240001

    Québec, Quebec, Canada

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.